Weill Medical College of Cornell University

• Home
• Cancer and Blood Disorders
  • Solid Tumor
    • Bladder Cancer
    • Breast Cancer
    • Colon Cancer
    • Esophageal Cancer
    • Gastric/Stomach Cancer
    • Head and Neck Cancer
    • Kidney/Renal Cancer
    • Liver Cancer
    • Lung Cancer
    • Melanoma
    • Ovarian/Peritoneal/Fallopian Tube Cancer
    • Pancreatic Cancer
    • Prostate Cancer
    • Sarcoma
    • Soft Tissue Cancer

  • Multiple Myeloma
  • Leukemia and Myeloproliferative Disorders
    • Acute Lymphocytic Leukemia
    • Acute Myeloid Leukemia
    • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    • Chronic Myeloid Leukemia
    • Myelodysplastic Syndrome
    • Myelofibrosis
    • Polycythemia Vera

  • Lymphoma
    • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    • Hodgkin’s Lymphoma
    • Non-Hodgkin’s Lymphoma
    • Waldenstrom’s Macroglobulinemia

  • Bone Marrow Transplant (BMT)
  • Benign Hematology
    • Anticoagulation
    • Bleeding and Platelet Disorders
• Cardiovascular/Heart
  • Aortic Aneurysms
  • Arrhythmias
  • Atrial Fibrillations
  • Coronary Artery Disease (CAD)
  • Hypertension/High Blood Pressure
  • Inherited Heart Disease
  • Myocardial Infarction
  • Other Cardiovascular Diseases and Conditions
• Diabetes
• Gastrointestinal Diseases
  • Hepatitis
    • Hepatitis B
    • Hepatitis C
    • Hepatitis/HIV Co-Infection
  • Cancers of the Colon, Pancreas, Esophagus, Stomach
  • Celiac Disease
  • Crohn's Disease
  • Inflammatory Bowel Disease
  • Ulcerative Colitis
  • Other Gastrointestinal Diseases
• Geriatrics
  • Pain and Palliative Care
• Hepatitis
  • Hepatitis B
  • Hepatitis C
  • Hepatitis/HIV Co-infection
• HIV/AIDS and Infectious Diseases
• Kidney/Renal Disease
  • Kidney Transplants
• Lifestyle/Behavior Change
  • Medication Adherence
  • Hypertension Control
  • Colon Cancer Screening/Risk Reduction
• Pulmonary (Lung/Respiratory Tract) Disease
  • Asthma
  • Pneumonia
  • Pulmonary Fibrosis
  • Smokers
  • Other Respiratory/Lung Conditions
• Rheumatology Autoimmune Disease and Orthopedic Surgery
 
• Sleep Disorders
• Weight Loss/Obesity
• Healthy Volunteers

Phase I trial of anti-CD74 (hLL1) Antibody Therapy in B-cell malignancies

Study Status

Closed to Enrollment

Study Description

Previous expericence with antibody therapy in both non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) suggests the need for further exploration of new antibody treatments for these diseases. 

This is a Phase I, open-label study being conducted in patients with recurrent non-Hodgkin's lymphoma or chronic lymphocytic leukemia who have progressed after at least one prior standard treatment.  All patients will receive hLL1 (humanized anti-CD74 monoclonal antibody) administered intravenously daily, five days per week (Monday to Friday), for two weeks at one of 4 planned dose levels. Treatment occurs over 2 weeks, with post-treatment evaluations over 12 weeks. Follow-up is required in all patients until resolution of any treatment-related abnormalities or until relapse occurs.

Click here to visit our lymphoma blog.

Sponsor

Weill Cornell Medical College; Immunomedics, Inc.

Key Eligibility

• Men and women age 18 and older
  
• Confirmed diagnosis of recurrent B cell non-Hodgkin's lymphoma or recurrent chronic lymphocytic leukemia
  
• Has received at least one prior treatment with standard chemotherapy and at least one prior treatment with rituximab
  
• Has not received anti-cancer therapy within 28 days of treatment, unless disease progression has been demonstrated and toxicities from prior therapy have resolved
  
• More detailed eligibility discussed when you contact the study team

Principal Investigator

John Leonard, MD

Contact

• June Greenberg, RN
• (212) 746-2651
• jdg2002@med.cornell.edu